Gyroscope Therapeutics Ltd is a private company founded by Syncona and Cambridge Enterprise and supported by its scientific founders with expertise in ophthalmology, immunology, gene therapy and targeted surgical delivery.
Our mission is to develop genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system.
Our global management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at multiple innovative biotech and pharmaceutical companies. Through our subsidiary, Orbit Biomedical, we also have significant surgical device development and surgeon training capabilities.
The company is headquartered close to London, UK with US offices close to Philadelphia, PA.